Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 168.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,814,219 shares of the company’s stock after acquiring an additional 1,138,423 shares during the period. Teva Pharmaceutical Industries accounts for approximately 1.0% of Clal Insurance Enterprises Holdings Ltd’s investment portfolio, making the stock its 27th biggest holding. Clal Insurance Enterprises Holdings Ltd owned approximately 0.18% of Teva Pharmaceutical Industries worth $39,078,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the business. Dimensional Fund Advisors LP raised its position in shares of Teva Pharmaceutical Industries by 16.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,185,541 shares of the company’s stock valued at $20,261,000 after acquiring an additional 168,658 shares in the last quarter. Legal & General Group Plc raised its position in shares of Teva Pharmaceutical Industries by 14.6% during the 1st quarter. Legal & General Group Plc now owns 611,919 shares of the company’s stock valued at $10,458,000 after acquiring an additional 77,766 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $293,000. Cibc Bank USA acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $270,000. Finally, DnB Asset Management AS raised its position in shares of Teva Pharmaceutical Industries by 13.6% during the 2nd quarter. DnB Asset Management AS now owns 77,700 shares of the company’s stock valued at $1,890,000 after acquiring an additional 9,300 shares in the last quarter. Hedge funds and other institutional investors own 64.73% of the company’s stock.
In other news, VP Richard Daniell sold 2,488 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at $58,940.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the transaction, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. In the last three months, insiders sold 10,350 shares of company stock valued at $239,430. Company insiders own 0.43% of the company’s stock.
TEVA has been the topic of several research reports. Zacks Investment Research raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a research report on Monday, July 9th. Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, August 7th. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective for the company in a research note on Monday, October 1st. Finally, Morgan Stanley upped their price objective on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $20.94.
Shares of TEVA opened at $23.00 on Friday. The firm has a market cap of $20.09 billion, a P/E ratio of 5.85, a P/E/G ratio of 1.62 and a beta of 0.71. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86. Teva Pharmaceutical Industries Ltd has a 12 month low of $10.85 and a 12 month high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The company had revenue of $4.70 billion during the quarter, compared to analysts’ expectations of $4.75 billion. During the same quarter in the prior year, the business posted $1.02 earnings per share. The company’s revenue for the quarter was down 17.8% compared to the same quarter last year. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.7 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.